Is interleukin-17 implicated in early knee osteoarthritis pathogenesis as in rheumatoid arthritis?

Egyptian Rheumatology and Rehabilitation - Tập 49 Số 1 - 2022
Hoda Mohamed Abdel-Naby1, Sarah Sayed El-Tawab1, Mohamed M. Rizk2, N. Aboeladl3
1Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2Clinical and Chemical pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
3Rheumatology and Rehabilitation, Faculty of Medicine, Helwan University, Cairo, Egypt

Tóm tắt

Abstract Background Interleukin-17 (IL-17) is a cytokine that promotes activation of multiple catabolic pathways resulting in cartilage and tissue damage. It has features making it increasingly attractive as a biological marker, especially in rheumatoid arthritis (RA) and osteoarthritis (OA). However, its expression is heterogeneous; not all patients’ exhibit high IL-17 levels, and its level along the disease course is still challenging to predict. Aim of the work The objectives of this study were to compare serum IL-17 levels in patients with early knee OA and in RA patients, to determine its correlation with disease activity in RA and to determine if it is correlated with functional scores in both RA and OA. Subjects and methods Twenty early knee OA patients (32.7 ± 3.7) years were included. Diagnosis of early OA was based on Luyten et al. 2012 early knee OA classification (early OA 2012). This study also included 25 RA patients aged 32.8 ± 5.1 years, and the diagnosis was according to 2010 ACR-EULAR classification criteria for RA. The current work also included a control group of 20 healthy volunteers aged 31.9 ± 3.2 years. The serum IL-17 level was assessed by using the ELISA technique. Results Serum IL-17 level was significantly high in early knee OA patients (5.2 pg/ml) and was significantly higher in RA patients (5.9 pg/ml) compared to the control group (4.9 pg/ml) (P < 0.001). Conclusions The increased serum IL-17 level in patients with early knee OA suggests its pathogenic role in the disease. Serum IL-17 positive correlation with the severity of knee OA-related pain proposes that it may be a potential marker to target for early treatment of knee OA-related pain.

Từ khóa


Tài liệu tham khảo

Van Steenbergen HW, da Silva JAP, Huizinga TWJ et al (2018) Preventing progression from arthralgia to arthritis: targeting the right patients. Nat Rev Rheumatol 14:32–41

Karsdal MA, Michaelis M, Ladel C et al (2016) Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. Osteoarthritis Cartilage 24:2013–2021

Roos EM, Arden NK (2016) Strategies for the prevention of knee osteoarthritis. Nat Rev Rheumatol 12:92–101

Tanasescu C, Balanescu E, Balanescu P et al (2010) IL-17 in cutaneous lupus erythematosus. Eur J Intern Med 21(3):202–207

Katz LH, Kopylov U, Fudim E et al (2014) Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn’s disease treated with anti-TNF antibodies. Clin Res Hepatol Gastroenterol 38(4):491–498

Chiricozzi A (2014) Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr 105(Suppl 1):9–20

Raychaudhuri SP (2013) Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44(2):183–193

Sexton M, Cudaback E, Abdullah RA et al (2014) Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology 22(5):295–303

Elain G, Jeanneau K, Rutkowska A et al (2014) The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia 62(5):725–735

Kallaur AP, Oliveira SR, Colado Simão AN et al (2013) Cytokine profile in relapsingremitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep 7(3):1010–1020

Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129(3):311–321

Reinert-Hartwall L, Honkanen J, Salo HM et al (2015) Th1/Th17 plasticity is a marker of advanced beta cell autoimmunity and impaired glucose tolerance in humans. J Immunol 194(1):68–75

Wojdasiewicz P, Poniatowski LA, Szukiewicz D (2014) The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm 2014:561459

Roşu A, Mărgăritescu C, Stepan A et al (2012) IL-17 patterns in synovium, serum and synovial fluid from treatment-naive, early rheumatoid arthritis patients. Rom J Morphol Embryol 53(1):73–80

Sarkar S, Justa S, Brucks M et al (2014) Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis. Clin Exp Immunol 177(3):652–661

Scanzello CR, Goldring SR (2012) The role of synovitis in osteoarthritis pathogenesis. Bone 51:249–257. https://doi.org/10.1016/j.bone.2012.02.012

Robert M, Miossec P (2019) IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels. Front Med 5:364

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581

Luyten FP, Denti M, Filardo G et al (2012) Definition and classification of early osteoarthritis of the knee. Knee Surg Sports Traumatol Arthrosc 20:401–406

Altman R, Asch E, Bloch D, Bole D, Borenstein K, Brandt K et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 29:1039–1049

Prevoo MLL, Hof v’t MA, Kuper HH, van MA L, van de LBA P, van PLCM R (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

Wolfe F (2000) A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 43:2751–2761

Knee injury & Osteoarthritis Outcome Score (KOOS), English version LK1.0; available at www.KOOS.nu.

Chu CR, Williams AA, Coyle CH et al (2012) Early diagnosis to enable early treatment of pre-osteoarthritis. Arthritis Res Ther 14:212

Oliver J, Silman AJ (2009) Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 35:169–174

Ghaffari SA, Nemati M, Hajghani H et al (2017) Circulating concentrations of interleukin (IL)-17 in patients with multiple sclerosis: evaluation of the effects of gender, treatment, disease pattern and IL-23 receptor gene polymorphism. Iran J Neurol 16(1):15–25

Al-Saadany H, Hussein M, Gaber R, Zaytoun H (2016) Th-17 cells and serum IL-17 in rheumatoid arthritis patients: Correlation with disease activity and severity. Egypt Rheumatol 38(1):1–7

Korayem HK, Rezk MM, Hassan MM, El-Tawab SS, Elsaid NA (2016) Relation between serum IL-17 level and risk of osteoporotic fracture in premenopausal rheumatoid arthritis patients: Clinical, radiological and laboratory studies. Egypt Rheumat 38(2):85–90

Kay J, Morgacheva O, Messing SP (2014) Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 16(1):R40

Yue C, You X, Zhao L, Wang H, Tang F, Zhang F et al (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30(12):1553–1557

Leeb BF, Andel L, Leder S, Leeb BA, Rintelen B (2005) The patient's perspective and rheumatoid arthritis disease activity indexes. Rheumatology 44(3):360–365

Abu Al-Fadl EM, Ismail MA, Thabit M, El-Serogy Y (2014) Assessment of health-related quality of life, anxiety and depression in patients with early rheumatoid arthritis. Egypt Rheumatol 36(2):51–56

Wickrematilake G, Wijeratne L (2013) Assessing the impact of rheumatoid arthritis on quality of life in a group of patients attending a rheumatology clinic in Sri Lanka. Ind J Rheumatol 8:14–18

Chemin K, Gerstner C, Malmström V (2019) Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis. Front. Immunol 10:353

Favero M, Ramonda R, Goldring MB, Goldring SR, Punzi L (2015) Early knee osteoarthritis. RMD Open 1(Suppl 1):e000062

Chen B, Deng Y, Tan Y, Qin J, Chen L-B (2014) Association between severity of knee osteoarthritis and serum and synovial fluid interleukin 17 concentrations. J Int Med Res 42(1):138–144

Liu Y, Peng HDE, Meng ZFG, Wei M, Liu Abc Y, Peng HDE et al (2015) Correlation of IL-17 level in synovia and severity of knee osteoarthritis. Med Sci Monit 21:1732–1736

Wang K, Xu J, Cai J, Zheng S, Han W, Antony B et al (2016) Serum levels of interleukin-17 and adiponectin are associated with infrapatellar fat pad volume and signal intensity alteration in patients with knee osteoarthritis. Arthritis Res Ther 18:193

Wang K, Xu J, Cai J, Zheng S, Yang X, Ding C (2017) Serum levels of resistin and interleukin-17 are associated with increased cartilage defects and bone marrow lesions in patients with knee osteoarthritis. Mod Rheumatol 27(2):339–344

Han L, Lee HS, Yoon JH, Choi WS, Park YG, Nam SW et al (2014) Association of IL-17A and IL-17F single nucleotide polymorphisms with susceptibility to osteoarthritis in a Korean population. Gene 533(1):119–122

Na HS, Park J-S, Cho K-H, Kwon JY et al (2020) Interleukin-1-Interleukin-17 signaling axis induces cartilage destruction and promotes experimental osteoarthritis. Front Immunol 11:730. https://doi.org/10.3389/fimmu.2020.00730

Edd SN, Giori NJ, Andriacchi TP (2015) The role of inflammation in the initiation of osteoarthritis after meniscal damage. J Biomech 48:1420–1426

Scanzello CR, McKeon B, Swaim BH et al (2011) Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms. Arthritis Rheum 63:391–400

Martin JA, Brown T, Heiner A et al (2004) Post-traumatic osteoarthritis: the role of accelerated chondrocyte senescence. Biorheology 41:479–491

Martin JA, McCabe D, Walter M (2009) N-acetylcysteine inhibits post-impact chondrocyte death in osteochondral explants. J Bone Joint Surg Am 91:1890–1897

José MG, de Morales R, Puig L et al (2020) Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev 19(1):102429

Gao S, Mao C, Cheng J, Deng Q, Sheng W (2020) Association of IL-17A-197G/A and IL-17F-7488T/C polymorphisms and osteoarthritis susceptibility: a meta-analysis. Int J Rheum Dis 23:37–46. https://doi.org/10.1111/1756-185X.13737

Shao M, Shanshan X, Yang H, Wei X et al (2020) Association between IL-17A and IL-17F gene polymorphism and susceptibility in inflammatory arthritis: a meta-analysis. Clin Immunol 213:108374

Mimpen JY et al (2020) Interleukin-17A, -F, and -AF induce expression of pro-inflammatory genes in end-stage osteoarthritis chondrocytes and synovial fibroblasts. Osteoarthr Cartil 28:S114

Martel-Pelletier J, Barr AJ, Cicuttini FM et al (2016) Osteoarthritis. Nat Rev Dis Primers 2:16072

Snelling SJ, Bas S, Puskas GJ et al (2017) Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PLoS One 12(4):e0175109

Griffin TM, Lories RJ (2020) Cracking the code on the innate immune program in OA. Osteoarthr Cartil 28(5):529–531. https://doi.org/10.1016/j.joca.2020.03.013

Kraus VB, Birmingham J, Stabler TV et al (2012) Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthr Cartil 20:271–278

Sinkeviciute D, Aspberg A, He Y et al (2020) Characterization of the interleukin-17 effect on articular cartilage in a translational model: an explorative study. BMC Rheumatol 4:30. https://doi.org/10.1186/s41927-020-00122-x

Mahmoudian A, Van Assche D, Herzog W, Luyten FP (2018) Towards secondary prevention of early knee osteoarthritis. RMD Open 4(2):e000468. Published 2018 Aug 13. https://doi.org/10.1136/rmdopen-2017-000468

Thông tin
Thông tin xuất bản

Egyptian Rheumatology and Rehabilitation

Tập 49 Số 1

Thông tin tác giả